Geron Corporation (GERN)
Develops cancer drugs targeting telomerase to treat blood disorders and leukemia.
$1.45-0.02%Healthcare
StockGlow Score
Leaning Bullish
BearishBullish
1 year ago+23.9%
The outlook
Analysts lean bullish on GERN with a "Buy" consensus, and the stock is trading above both its 50- and 200-day averages. The price sits roughly midway in its 52-week range, while the average analyst target sits about 193% above the current price. Overall sentiment leans constructive based on available data.
What’s behind the score
Analyst consensusBuy — 1.6 avg of 4 analysts
Price trendAbove its 50- & 200-day averages
52-week range42% of the way from its 52-week low to high
Price targetAvg target +193% vs current price
Analyst price target
~12-month · 4 analysts$4.25average target+193.1% vs now
Now $1.45
Low $3.00High $6.00
Published targets from Wall Street analysts (public data) — what analysts expect over roughly a year. This is not a StockGlow forecast and not a recommendation. Analyst targets are frequently wrong.
Market cap
$930.2M
52-wk high
$2.01
52-wk low
$1.04
50-day avg
$1.31
200-day avg
$1.40
Trailing P/E
—